Aletaha D - Search Results

1

Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.

Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, Ehlers L, Abril A, Appenzeller S, Cid MC, Dasgupta B, Duftner C, Grayson PC, Hellmich B, Hočevar A, Kermani TA, Matteson EL, Mollan SP, Neill L, Ponte C, Salvarani C, Sattui SE, Schmidt WA, Seo P, Smolen JS, Thiel J, Toro-Gutiérrez CE, Whitlock M, Buttgereit F. Dejaco C, et al. Among authors: aletaha d. Ann Rheum Dis. 2024 Jan 2;83(1):48-57. doi: 10.1136/ard-2022-223429. Ann Rheum Dis. 2024. PMID: 36828585 Free PMC article.

2

Advances in anti-inflammatory therapy.

Aletaha D, Smolen JS. Aletaha D, et al. Acta Med Austriaca. 2002;29(1):1-6. doi: 10.1046/j.1563-2571.2002.01037.x. Acta Med Austriaca. 2002. PMID: 11899747 Review.

3

Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis.

Aletaha D, Smolen JS. Aletaha D, et al. Arthritis Rheum. 2002 Apr 15;47(2):181-8. doi: 10.1002/art.10266. Arthritis Rheum. 2002. PMID: 11954012 Free article.

4

Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years.

Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Aletaha D, et al. Ann Rheum Dis. 2002 Jul;61(7):630-4. doi: 10.1136/ard.61.7.630. Ann Rheum Dis. 2002. PMID: 12079906 Free PMC article.

5

Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.

Aletaha D, Smolen JS. Aletaha D, et al. J Rheumatol. 2002 Aug;29(8):1631-8. J Rheumatol. 2002. PMID: 12180721

6

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.

Aletaha D, Smolen JS. Aletaha D, et al. Rheumatology (Oxford). 2002 Dec;41(12):1367-74. doi: 10.1093/rheumatology/41.12.1367. Rheumatology (Oxford). 2002. PMID: 12468815

7

Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis.

Aletaha D, Kapral T, Smolen JS. Aletaha D, et al. Ann Rheum Dis. 2003 May;62(5):482-6. doi: 10.1136/ard.62.5.482. Ann Rheum Dis. 2003. PMID: 12695166 Free PMC article.

8

The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Smolen JS, Aletaha D. Smolen JS, et al. Among authors: aletaha d. Curr Rheumatol Rep. 2003 Oct;5(5):336-40. doi: 10.1007/s11926-003-0014-8. Curr Rheumatol Rep. 2003. PMID: 12967513 No abstract available.

9

Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.

Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, Smolen JS. Aletaha D, et al. Ann Rheum Dis. 2003 Oct;62(10):944-51. doi: 10.1136/ard.62.10.944. Ann Rheum Dis. 2003. PMID: 12972472 Free PMC article.

10

Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.

Aletaha D, Smolen JS. Aletaha D, et al. Curr Rheumatol Rep. 2003 Dec;5(6):409-12. doi: 10.1007/s11926-003-0048-y. Curr Rheumatol Rep. 2003. PMID: 14609484 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page